Translational CNS Summit

Organization: Hanson Wade

Venue: DoubleTree Suites by Hilton Hotel Boston

Location: Boston, Massachusetts, United States

Event Date/Time: May 21, 2013 End Date/Time: May 23, 2013
Report as Spam



Increase the translational potential of your CNS therapies

Translational CNS Summit focuses on the biggest commercial opportunity to maximize the value of your CNS pipeline; improving the use of translational approaches

Unreliable animal models. Validation of new biomarkers. Detecting if a drug has reached the brain. Are all common challenges of CNS drug development. 

Translational CNS Summit will bring together CNS experts to find solutions to these challenges and more - to improve the translational potential of your entire CNS pipeline. Get more CNS therapies through to market, restore investor and management confidence and bring investment back into the CNS field. 

This meeting is fundamentally a summit, a meeting of leading minds in CNS. You can meet with and learn from commercial and academic leaders that will inspire new ideas and strategies to minimize clinical attrition, maximize pipeline potentialand see a return on historic investments made in the CNS field.

Attend Translational CNS Summit to:

  • Attract investment back to CNS drug development. Gain unprecedented insights into the CNS strategies of three top pharma companies, Pfizer, BMSand AbbVie. Learn how they are designing their CNS strategies to avoid the common pitfalls of CNS drug development
  • Design your imaging protocols and strategies to maximize its impact on drug development. Learn how imaging experts at AstraZeneca, Amgen andBoston Children’s Hospital are using imaging at the right time of development to optimize its effect on the translational potential of their pipeline
  • Develop animal models with an increased predictive validity even for the most complex disease types. Hear how model experts at Genzyme, Astellasand Novartis are developing better animal models and compensating for their unavoidable limitations
  • Improve the way you use biomarkers in drug development. Hear  how Merck, Biogen Idec and Janssen are using surrogate end points and back-translational approaches to minimize clinical attrition within their pipelines

Who should attend?

This meeting is for anyone who wants to be a part of deciding how we can increase the translational potential of CNS therapies. The following have already expressed an interest in being a part of the summit:

  • Large drug developers – Heads of CNS programmes and research scientists who would benefit from learning to apply new translational approaches
  • Small and medium drug developers who are looking to network with larger drug developers and or learn how to apply new translational approaches
  • Providers of services or products specifically targeted at people working in the CNS space
  • People from research institutes who are working on refining translational approaches that will benefit CNS drug development


400 Soldiers Field Rd
United States


Hanson Wade